Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

Core Insights - Halozyme Therapeutics and Skye Bioscience have entered a non-exclusive global collaboration to develop a subcutaneous formulation of nimacimab for obesity treatment, utilizing Halozyme's ENHANZE drug delivery technology [1][2] - The collaboration aims to evaluate higher doses of nimacimab through larger injection volumes, with Skye planning to initiate a Phase 2b clinical trial in mid-2026 [3] Group 1: Collaboration Details - Skye has licensed Halozyme's ENHANZE technology to support the development and commercialization of nimacimab, which is intended to enhance treatment options for obesity [1][2] - Skye will make milestone payments based on the achievement of specific development and commercialization events, while Halozyme will receive mid-single digit royalties on net sales of nimacimab for at least 10 years [2] Group 2: Market Potential and Strategy - The collaboration expands Halozyme's ENHANZE technology into the obesity market, which is identified as having significant long-term potential [2] - Halozyme's strategy focuses on driving sustainable royalty growth through new partnerships and innovations, reinforcing the scalability of ENHANZE across various therapeutic indications [2] Group 3: Clinical Development Plans - Skye plans to assess the combination of nimacimab with a GLP-1 receptor agonist in the upcoming Phase 2b clinical trial, which will evaluate multiple dose-ranging strategies [3][9] Group 4: Company Background - Halozyme is a biopharmaceutical company that develops solutions to improve patient experiences and outcomes, with a focus on drug delivery technologies [4][5] - The ENHANZE technology has been validated commercially and is licensed to numerous leading pharmaceutical companies, enhancing its market presence [5] Group 5: Future Innovations - Halozyme is also developing Hypercon™, a microparticle technology aimed at reducing injection volumes while expanding the scope of therapeutics that can be delivered subcutaneously [6] - The company is engaged in developing drug-device combination products to improve patient comfort and adherence [7]